---
title: GLP-1 Ocular Safety Monitoring at Point-of-Need
description: "Practical advice for GLP-1 Ocular Safety Monitoring: reduce rework, standardize exams, and keep NAION surveillance audit-ready with certified staff."
---

[Eyes on Research ](https://www.2020onsite.com/eyes-on-research)

# [GLP-1 Ocular Safety Monitoring at Point-of-Need](https://www.2020onsite.com/eyes-on-research/glp-1-ocular-safety-monitoring-at-point-of-need)

 Written by [20/20 Onsite](https://www.2020onsite.com/eyes-on-research/author/2020-on-site) | Sep 4, 2025 6:08:34 PM

In today’s funding environment, sponsors cannot afford preventable rework on ocular endpoints. Regulators are closely examining a potential link between GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy (NAION). 

[Recent epidemiological data](https://www.2020onsite.com/eyes-on-research/glp-1-clinical-trial-eye-safety-semaglutide-eye-risks?hsLang=en)  
show semaglutide exposure doubles [NAION](https://www.2020onsite.com/eyes-on-research/breaking-research-semaglutide-use-and-increased-risk-of-naion-implications-for-clinical-trials-and-patient-safety?hsLang=en) risk (hazard ratio 2.19), though absolute risk remains low—about one extra case per 10,000 person-years. 

In June 2025, the [European Medicines Agency’s PRAC](https://www.2020onsite.com/eyes-on-research/glp-1-clinical-trial-eye-safety-semaglutide-eye-risks?hsLang=en) concluded NAION is a “very rare” side effect of semaglutide and updated product labels accordingly. Sponsors should expect heightened scrutiny of GLP-1 ocular safety monitoring plans and study records.

### What Is Needed for GLP-1 Ocular Safety Monitoring

- **Enhanced Screening Procedures****  
  ** Implement protocol-appropriate baseline and periodic comprehensive eye exams (BCVA, anterior and posterior segment ocular health assessments, fundus imaging, OCT when indicated) to establish ocular health status before and during treatment.
- **Rapid Adverse-Event Detection****  
  ** Define and document clear workflows for immediate evaluation when participants report sudden vision changes, enabling real-time identification and management of NAION signals.
- **Audit-Ready Documentation**  
  Maintain standardized device calibration logs, QC-approved source documentation, technician competency records, deviation logs, and visit-level checklists mapped to protocol requirements.

### How 20/20 Onsite Operationalizes GLP-1 Ocular Safety Monitoring

20/20 Onsite delivers standardized [ophthalmic assessments](https://www.2020onsite.com/clinical-trials-research-phase-1-3?hsLang=en) at the point of need—on-site, near patients, or in community settings—so you capture protocol-compliant data on the first attempt and keep your audit file inspection-ready.

- **Standardized Equipment****  
  **Locked device models/firmware for OCT and fundus cameras, with daily calibration and auditable logs.
- **Certified Personnel****  
  **Ophthalmic technicians and physicians trained on study-specific procedures (e.g., BCVA, OCT Imaging, Fundus Photography) operating under sponsor/CRO SOPs.
- **Centralized Oversight & Documentation****  
  **Documentation tracks first-time-right rate, retake metrics, and query counts. All calibration certificates, training records, and logs are stored in an inspection-ready audit repository.

### Key Benefits

- Reduces variability across multi-site programs with identical devices, settings, and workflows.
- Cuts avoidable rework by catching QC flags while participants are still on-site.
- Keeps ocular endpoint files continuously inspection-ready, not just before audits.

### Why Now?

- EMA PRAC has updated semaglutide product information to include NAION as a very rare side effect.
- Post-marketing surveillance and real-world evidence initiatives highlight the need for proactive ocular safety monitoring.

### A Practical Path You Can Start This Month

1. **Ocular Endpoint Risk Scan****  
   **Map your schedule of assessments to operational risks by visit and modality; confirm device specs, calibration plan, and training requirements.
2. **Activation****  
   **Stage calibrated equipment, finalize SOP alignment, run mock visits, validate data flows, and activate live-QC dashboards (first-time-right, retake rate, query rate).
3. **Steady-State Operations & Reporting****  
   **Deploy mobile capacity as needed, maintain daily calibration and live QC, and keep an organized, monitor-friendly audit file.

## Talk to Our Team (No Obligation)

Planning or running a GLP-1 study with ocular endpoints? Schedule a 30-minute consultation to review your protocol and site footprint. We’ll deliver a focused risk map (devices, training, QC, documentation) and a [right-sized deployment option](https://www.2020onsite.com/contact-us?hsLang=en) to strengthen your GLP-1 ocular safety monitoring.

[Schedule Your Consultation → Understand Your Risk](https://www.2020onsite.com/contact-us?hsLang=en)

>>> [Download the GLP-1 and Neuro ebook](https://www.2020onsite.com/ebook-critical-imaging-risks-in-glp-1-and-neurology-studies?hsLang=en): The Clinical Imaging Strategy That Safeguards Your Trial's Ocular Endpoints <<<

[View full post](https://www.2020onsite.com/eyes-on-research/glp-1-ocular-safety-monitoring-at-point-of-need)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "20/20 Onsite"
  },
  "dateModified" : "2025-09-16T17:51:13.113Z",
  "datePublished" : "2025-09-04T18:08:34Z",
  "headline" : "GLP-1 Ocular Safety Monitoring at Point-of-Need",
  "image" : {
    "@type" : "ImageObject",
    "height" : 500,
    "url" : "https://1771763.fs1.hubspotusercontent-na1.net/hubfs/1771763/GLP-1%20Ocular%20Safety%20Monitoring%20at%20Point-of-Need.png",
    "width" : 900
  },
  "mainEntityOfPage" : "https://www.2020onsite.com/eyes-on-research/glp-1-ocular-safety-monitoring-at-point-of-need",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Eyes on Research"
  }
}
```